160 related articles for article (PubMed ID: 31959167)
1. Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial.
Divo MJ; DePietro MR; Horton JR; Maguire CA; Celli BR
Respir Res; 2020 Jan; 21(1):26. PubMed ID: 31959167
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.
Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C
Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947
[TBL] [Abstract][Full Text] [Related]
3. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
[TBL] [Abstract][Full Text] [Related]
4. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
[TBL] [Abstract][Full Text] [Related]
5. Effect of indacaterol on lung deflation improves cardiac performance in hyperinflated COPD patients: an interventional, randomized, double-blind clinical trial.
Santus P; Radovanovic D; Di Marco S; Valenti V; Raccanelli R; Blasi F; Centanni S; Bussotti M
Int J Chron Obstruct Pulmon Dis; 2015; 10():1917-23. PubMed ID: 26392766
[TBL] [Abstract][Full Text] [Related]
6. Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
Brusasco V; Canonica GW; Dal Negro R; Scano G; Paggiaro P; Fabbri LM; Barisione G; D'Amato G; Varoli G; Baroffio M; Milanese M; Mereu C; Crimi E
J Aerosol Med Pulm Drug Deliv; 2011 Oct; 24(5):235-43. PubMed ID: 21689019
[TBL] [Abstract][Full Text] [Related]
7. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia.
Lee SD; Xie CM; Yunus F; Itoh Y; Ling X; Yu WC; Kiatboonsri S
Respirology; 2016 Jan; 21(1):119-27. PubMed ID: 26394882
[TBL] [Abstract][Full Text] [Related]
9. Deterioration of Nighttime Respiratory Mechanics in COPD: Impact of Bronchodilator Therapy.
Domnik NJ; James MD; Scheeren RE; Ayoo GA; Taylor SM; Di Luch AT; Milne KM; Vincent SG; Phillips DB; Elbehairy AF; Crinion SJ; Driver HS; Neder JA; O'Donnell DE
Chest; 2021 Jan; 159(1):116-127. PubMed ID: 32603714
[TBL] [Abstract][Full Text] [Related]
10. 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD.
Reisner C; Gottschlich G; Fakih F; Koser A; Krainson J; Delacruz L; Arora S; Feldman G; Pudi K; Siddiqui S; Orevillo C; Maes A; St Rose E; Martin U
Respir Res; 2017 Aug; 18(1):157. PubMed ID: 28821260
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the acute effect of tiotropium versus a combination therapy with single inhaler budesonide/formoterol on the degree of resting pulmonary hyperinflation.
Santus P; Centanni S; Verga M; Di Marco F; Matera MG; Cazzola M
Respir Med; 2006 Jul; 100(7):1277-81. PubMed ID: 16337781
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of adding budesonide/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China.
Huang K; Guo Y; Kang J; An L; Zheng Z; Ma L; Peng L; Wang H; Su R; Itoh Y; Wang C
Ther Adv Respir Dis; 2019; 13():1753466619853500. PubMed ID: 31240995
[TBL] [Abstract][Full Text] [Related]
13. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
Lindberg A; Szalai Z; Pullerits T; Radeczky E
Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
[TBL] [Abstract][Full Text] [Related]
14. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease.
O'Donnell DE; Voduc N; Fitzpatrick M; Webb KA
Eur Respir J; 2004 Jul; 24(1):86-94. PubMed ID: 15293609
[TBL] [Abstract][Full Text] [Related]
15. Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap.
Ishiura Y; Fujimura M; Ohkura N; Hara J; Kasahara K; Ishii N; Sawai Y; Shimizu T; Tamaki T; Nomura S
Int J Chron Obstruct Pulmon Dis; 2020; 15():269-277. PubMed ID: 32103926
[TBL] [Abstract][Full Text] [Related]
16. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
[TBL] [Abstract][Full Text] [Related]
17. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
Watz H; Mailänder C; Baier M; Kirsten A
BMC Pulm Med; 2016 Jun; 16(1):95. PubMed ID: 27301417
[TBL] [Abstract][Full Text] [Related]
18. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD.
Berton DC; Reis M; Siqueira AC; Barroco AC; Takara LS; Bravo DM; Andreoni S; Neder JA
Respir Med; 2010 Sep; 104(9):1288-96. PubMed ID: 20580216
[TBL] [Abstract][Full Text] [Related]
19. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD.
Celli BR; Tashkin DP; Rennard SI; McElhattan J; Martin UJ
Respir Med; 2011 Aug; 105(8):1176-88. PubMed ID: 21531124
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD.
Williamson PA; Short PM; Clearie KL; Vaidyanathan S; Fardon TC; Howaniec LJ; Lipworth BJ
Chest; 2010 Sep; 138(3):595-604. PubMed ID: 20418370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]